Description of Measure | Prevalence of diabetes mellitus and glycemic control in the CKD population |
---|
Data Source | NCHS/CDC |
---|
Type of Data Source | Public |
---|
Data Set | NHANES |
---|
Health Care System Data | No |
---|
Regional or National? | National |
---|
Demographic Group | Noninstitutionalized U.S. residents aged 60 years or older |
---|
Numerator | Non-pregnant participants with completed surveys or fasting glucose levels who report having diabetes (or with elevated fasting glucose). |
---|
Denominator | Participants with CKD |
---|
Definition of CKD | Stage 1, eGFR ≥ 90 ml/min/1.73 m² and presence of single albuminuria; Stage 2, eGFR 60-89 ml/min/1.73 m² and presence of single albuminuria; Stage 3, eGFR 30-59 ml/min/1.73 m²; Stage 4, 15-29 ml/min/1.73 m²; Stage 5, excluded |
---|
Glomerular filtration rate | Estimated using CKD-EPI equation for calibrated creatinine: eGFR=141 x [min(calibrated serum creatinine in mg/dL) /κ, 1)]α x [max(calibrated serum creatinine in mg/dL/κ, 1)]κ x 0.993age x (1.018 if female) x (1.159 if non-Hispanic black)
κ = 0.7 if female, and 0.9 if male
α = -0.329 if female, and -0.411 if male |
---|
Proteinuria | Urinary albumin-to-creatinine ratios of 30-299 mg/g (microalbuminuria) and >300 mg/g (macroalbuminuria); pregnant women excluded |
---|
Primary Data Source Indicator | diq010: “Other than during pregnancy, have you ever been told by a doctor or health professional that you have diabetes or sugar diabetes?” yes/no |
---|
Primary Indicator Method of Measurement | Questionnaire (interviewer-administered); ages 1+ |
---|
Secondary (1) Variable | lbxglu: Fasting plasma glucose (subsample) |
---|
Secondary (1) Indicator Method of Measurement | Examination/Laboratory |
---|
Secondary (2) Variable | rhd143, rhd141/rhd140, urxpreg: current pregnancy |
---|
Secondary (2) Indicator Method of Measurement | Questionnaire (interviewer-administered) or exam (urine pregnancy status) |
---|
Secondary (3) Variable | nhcode/rxddrgid: generic drug codes |
---|
Secondary (3) Indicator Method of Measurement | Questionnaire (interviewer-administered), with recording of medications from Rx bottles |
---|
Frequency of Measurement (Primary) | Once (cross-sectional) |
---|
U.S. Region Covered by Primary Variable | All |
---|
Period Currently Available | 1999–2014 |
---|
Pending Data | 2015-2016 |
---|
Additional Data Items of Interest | Stage of CKD, stratification variables of interest (age, gender, race/ethnicity, BMI, hypertension by self-report) |
---|
Limitations of Indicator | Fasting plasma glucose only on a subsample of morning participants who were fasting; OGTT available for 2005-2014 only |
---|
Analytic Considerations | Appropriate NHANES survey weights, including fasting and OGTT weights, must be used for all analyses; glucose values must be converted for 2005-2006 and 2007-2008; OGTT only measured on those without diabetes |
---|
Age Adjustment |
Adjusted for the distribution of age within the sample.
|
---|